Amoeba S.A. buy melinda
Start price
22.07.21
/
50%
€1.42
Target price
22.07.22
€2.00
Performance (%)
-61.55%
End price
23.07.22
€0.55
Summary
This prediction ended on 23.07.22 with a price of €0.55. Massive losses of -61.55% were the result for the BUY prediction by melinda. melinda has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Amoeba S.A. | -7.129% | -7.129% | -8.503% | -68.330% |
iShares Core DAX® | 1.887% | 1.967% | 17.000% | 18.227% |
iShares Nasdaq 100 | 2.316% | -1.227% | 22.986% | 35.321% |
iShares Nikkei 225® | 1.134% | 0.390% | 9.520% | -0.898% |
iShares S&P 500 | 1.821% | 0.790% | 22.957% | 39.161% |
According to melinda what are the pros and cons of Amoeba S.A. for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by melinda for this prediction
In the thread Amoeba S.A. diskutieren
Buy mit Kursziel 2,0
In the thread Trading Amoeba S.A.
Die von melinda gewählte maximale Laufzeit wurde überschritten
Stopped prediction by melinda for Amoeba S.A.
Amoeba S.A.
Start price
Target price
Perf. (%)
€0.86
01.10.22
01.10.22
-
01.10.23
01.10.23
-51.16%
02.10.23
02.10.23
Could be worthwhile Investment >10% per year
Amoeba S.A.
Start price
Target price
Perf. (%)
€3.40
19.05.20
19.05.20
€4.80
04.11.21
04.11.21
-58.17%
22.07.21
22.07.21
Could be worthwhile Investment >10% per year
Amoeba S.A.
Start price
Target price
Perf. (%)
€5.25
13.07.18
13.07.18
€6.80
09.11.18
09.11.18
-4.95%
09.11.18
09.11.18
Could be worthwhile Investment >10% per year
Amoeba S.A.
Start price
Target price
Perf. (%)
€16.19
09.10.17
09.10.17
€25.00
27.12.17
27.12.17
-11.92%
27.12.17
27.12.17
Could be worthwhile Investment >10% per year
Amoeba S.A.
Start price
Target price
Perf. (%)
€16.19
09.10.17
09.10.17
€25.00
27.12.17
27.12.17
-11.92%
27.12.17
27.12.17
Could be worthwhile Investment >10% per year
Amoeba S.A.
Start price
Target price
Perf. (%)
€15.40
06.05.17
06.05.17
€30.00
09.05.17
09.05.17
10.39%
09.05.17
09.05.17
Could be worthwhile Investment >10% per year